

Eight new cytotoxic annonaceous acetogenins from the seeds of *Annona squamosa*

MA Cheng-Yao¹, LU Jia-Hui¹, LI Xiang^{1*}, LIU Xiao², CHEN Jian-Wei^{1*}

¹ Pharmaceutical Institute, Nanjing University of Chinese Medicine, Nanjing 210023, China;

² Engineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing 210023, China

Available online 20 Apr., 2019

[ABSTRACT] Eight new annonaceous acetogenins, squamotin A–D (**1–4**), annosquatin IV–V (**5** and **6**), muricin O (**7**) and squamosten B (**8**), together with four known ones (**9–12**) were isolated from the seeds of *Annona squamosa*. Their structures were elucidated by chemical methods and spectral data. The inhibitory activities of compound **1–9** against three multidrug resistance cell lines were evaluated. All tested compounds showed strong cytotoxicity.

[KEY WORDS] *Annona squamosa*; Annonaceous acetogenins; Cytotoxicity; Multidrug resistance

[CLC Number] R284 **[Document code]** A **[Article ID]** 2095-6975(2019)04-0291-07

Introduction

Annona squamosa Linn., a species of the genus *Annonaceae*, had been used as folkloric medicine in many tropical and subtropical regions^[1]. Srikaya, the fruit of *A. squamosa*, is extensively used to prepare candies, ice creams and beverages in tropics. Seeds of *A. squamosa* are mostly regarded as wastes and throw away. However, seeds accumulate toxic or health-beneficial compounds^[2]. Seeds of *A. squamosa* were reported with several biological activities, such as anticancer^[3], anti-parasitic^[4] and anti-fungal^[5]. Previous phytochemical and pharmacological investigations on seeds showed that annonaceous acetogenins (ACGs) are the main bioactive compounds^[6]. In our previous work, three new ACGs were isolated from the seeds of *A. squamosa*, and showed promising anticancer activities^[1,7]. In this study, the phytochemical investigation of *A. squamosa* seeds led to the isolate of eight new ACGs squamotin A–D (**1–4**), annosquatin IV–V (**5** and **6**), muricin O (**7**), squamosten B (**8**) along with four known ones gigantecin (**9**)^[8], neoannonin (**10**)^[9], squamocin-I (**11**)^[10],

squamostatin D (**12**)^[11], whose structural elucidation and cytotoxicity against multidrug resistance cancer of compound **1–9** were reported herein.

Result and discussion

Compound **1** had the molecular formula of C₃₇H₆₆O₇ from HR-ESIMS data (m/z 623.4921 [M + H]⁺, calcd. for 623.4881). A positive reaction to Raymond's reagent indicated the presence of a terminal α , β -unsaturated γ -lactone. In its NMR data, the signals at δ_H 7.00 (1H, d, $J=1.7$ Hz, H-35), 5.01 (1H, dq, $J=6.8, 1.8$ Hz, H-36), 1.42 (3H, d, $J=6.8$ Hz, H-37) and δ_C 173.9 (C-1), 134.4 (C-2), 148.9 (C-35), 77.4 (C-36), 19.2 (C-37) testified the existence of the terminal lactone. The proton signal at δ_H 2.28 (2H, t, $J=7.6$ Hz, H-3) suggested the absence of a hydroxyl group at the C-4 position^[3]. The signals at δ_H 3.83–3.97 (5H, m, H-26, 25, 22, 21, 18), 3.39–3.44 (1H, m, H-17) and δ_C 83.3 (C-18), 82.8 (C-25), 82.5 (C-22), 82.2 (C-21), 74.1 (C-17), 71.4 (C-26) are characteristic of the presence of two adjacent bistetrahydrofuran rings flanked by two OH groups. The relative stereochemistry of them was determined to be *th/t/th/t/er* (*threo/trans/threo/trans/erythro*) by comparison of NMR data with a series of bullatacin-type compounds^[12–13]. The bis-THF moiety was located from C-17 to C-26 by carefully analysis of the ESIMS fragment ions at m/z 417, 293, 265, 177 (Fig. 2). The third hydroxyl group was appeared in NMR spectrum at δ_H 3.58–3.61 (1H, m, H-10) and δ_C 71.8 (C-10). The location of this hydroxyl group was confirmed by the ESI-MS/MS fragment ion at m/z 377 (Fig. 2).

[Received on] 12-Nov.-2018

[Research funding] This work was supported by the National Natural Science Foundation of China (Nos. 81573577, 81274057 and 81403082).

[*Corresponding author] E-mail: lixiang_8182@163.com (LI Xiang); chenjw695@126.com (CHEN Jian-Wei)

These authors have no conflict of interest to declare.

Published by Elsevier B.V. All rights reserved






Fig. 1 Structures of annonaceous acetogenins 1–12




Fig. 2 Diagnostic ESIMS² fragment ions (m/z) of compounds 1–8

Compound **2** was isolated as a white waxy. The molecular formula was established as $C_{37}H_{66}O_6$ by HR-ESIMS (m/z 607.5068 [$M + H$]⁺, calcd. for 607.4932). The positive reaction of Raymond's reagent suggested the presence of a terminal lactone. Comparison of its NMR data (Tables 1 and 2)

with those of **1**, indicated that the relative of bis-THF unit of **2** is closely similar to **1**. The only difference was the absence of a hydroxyl group (δ_C 71.8 and δ_H 3.58–3.61) in **2**. The placement of bis-THF unit was located at C-8 to C-17 by analysis of the ESI-MS² fragments at m/z 417, 387, 267, 249, 167 (Fig. 2).

Table 1 ¹³C NMR spectral data of compounds 1–8 (101 MHz in CDCl₃)

Position	1	2	3	4	5	6	7	8
1	173.9	173.9	173.9	173.9	174.6	173.9	174.7	174.7
2	134.4	134.4	134.4	134.3	131.2	134.3	131.1	131.1
3	25.2	25.2	25.2	25.2	33.4	25.2	33.3	33.4
4	27.4	27.4	27.4	27.4	70.0	27.4	69.9	69.9
5	24.6–29.7	24.5–29.7	25.7–29.7	22.7–29.7	37.4	22.7–33.5	37.4	25.5–29.7
6	24.6–29.7	24.5–29.7	25.7–29.7	22.7–29.7	22.7–29.7	22.7–33.5	25.5–29.9	25.5–29.7
7	24.6–29.7	33.4	33.5	22.7–29.7	22.7–29.7	22.7–33.5	25.5–29.9	25.5–29.7
8	24.6–29.7	74.1	74.1	22.7–29.7	22.7–29.7	35.7	25.5–29.9	25.5–29.7
9	37.3	83.2	83.2	22.7–29.7	35.6	79.4	25.5–29.9	37.3
10	71.8	28.4	28.4	22.7–29.7	79.3	22.7–33.5	79.4	71.5
11	37.5	29.2	29.2	31.9	32.6	22.7–33.5	28.4	37.4
12	24.6–29.7	82.3	81.8	74.2	28.4	82.0	32.4	25.5–29.7
13	24.6–29.7	82.5	81.8	74.6	82.0	74.1	81.8	25.5–29.7
14	24.6–29.7	28.9	28.9	31.9	74.5	22.7–33.5	74.5	25.5–29.7
15	24.6–29.7	25.7	25.7	32.9	22.7–29.7	22.7–33.5	35.5	25.5–29.7
16	33.3	82.8	83.2	74.2	22.7–29.7	74.3	25.5–29.9	33.3
17	74.1	71.4	74.1	83.5	74.6	82.7	33.5	74.3
18	83.3	32.5	33.5	28.5	83.3	22.7–33.5	74.3	82.5
19	28.4	24.5–29.7	25.7–29.7	29.0	28.6	22.7–33.5	74.5	28.8
20	29.2	24.5–29.7	25.7–29.7	82.0	25.2	82.7	25.5–29.9	28.8
21	82.2	24.5–29.7	25.7–29.7	82.7	82.2	74.5	25.5–29.9	82.8
22	82.5	24.5–29.7	25.7–29.7	29.0	71.6	32.4	25.5–29.9	74.1
23	28.9	24.5–29.7	25.7–29.7	25.6	32.4	22.7–33.5	25.5–29.9	33.4
24	25.7	24.5–29.7	25.7–29.7	82.8	22.7–29.7	22.7–33.5	25.5–29.9	25.5–29.7
25	82.8	24.5–29.7	25.7–29.7	71.4	22.7–29.7	22.7–33.5	25.5–29.9	25.5–29.7
26	71.4	24.5–29.7	25.7–29.7	32.9	22.7–29.7	22.7–33.5	25.5–29.9	25.5–29.7
27	32.4	24.5–29.7	25.7–29.7	22.0–29.7	22.7–29.7	22.7–33.5	25.5–29.9	25.5–29.7
28	24.6–29.7	24.5–29.7	25.7–29.7	22.0–29.7	22.7–29.7	22.7–33.5	25.5–29.9	25.5–29.7
29	24.6–29.7	24.5–29.7	25.7–29.7	22.0–29.7	22.7–29.7	22.7–33.5	25.5–29.9	25.5–29.7
30	24.6–29.7	24.5–29.7	25.7–29.7	22.0–29.7	22.7–29.7	22.7–33.5	31.9	31.9
31	24.6–29.7	24.5–29.7	25.7–29.7	22.0–29.7	22.7–29.7	22.7–33.5	22.7	22.7
32	31.9	31.9	31.9	31.9	22.7–29.7	22.7–33.5	14.1	14.1
33	22.6	22.7	22.7	22.6	22.7–29.7	22.7–33.5	151.9	151.9
34	14.0	14.1	14.1	14.1	14.1	14.1	78.0	78.0
35	148.9	148.8	148.8	148.9	151.8	148.9	19.1	19.1
36	77.4	77.4	77.4	77.4	78.0	77.4	-	-
37	19.2	19.2	19.2	19.2	19.1	19.2	-	-

Table 2 ¹H NMR spectral data of new compounds (400 MHz in CDCl₃, J in Hz)

Position	1	2	3	4	5	6	7	8
3	2.28 (t, 7.6)	2.28 (t, 7.8)	2.28 (t, 7.8)	2.26 (t, 7.4)	2.41 (dd, 15.2, 8.3), 2.54 (dd, 15.1, 3.4)	2.28 (t, 7.7),	2.40 (dd, 15.1, 8.2), 2.52 (dd, 15.1, 3.3)	2.40 (dd, 15.1, 8.2), 2.51 (dd, 15.1, 3.3)
4	1.27–1.56 (m)	1.28–1.58 (m)	1.28–1.60 (m)	1.26–1.57 (m)	3.80–3.92 (m)	1.28–1.75 (m)	3.80–3.89 (m)	3.77–3.85 (m)
5	1.27–1.56 (m)	1.28–1.58 (m)	1.28–1.60 (m)	1.26–1.57 (m)	1.28–1.75 (m)	1.28–1.75 (m)	1.48–1.74 (m)	1.26–1.74 (m)
6	1.27–1.56 (m)	1.28–1.58 (m)	1.28–1.60 (m)	1.26–1.57 (m)	1.28–1.75 (m)	1.28–1.75 (m)	1.26–1.74 (m)	1.26–1.74 (m)
7	1.27–1.56 (m)	1.45–1.68 (m)	1.45–1.60 (m)	1.26–1.57 (m)	1.28–1.75 (m)	1.28–1.75 (m)	1.26–1.74 (m)	1.26–1.74 (m)
8	1.27–1.56 (m)	3.39–3.44 (m)	3.39–3.44 (m)	1.26–1.57 (m)	1.28–1.75 (m)	1.49–1.75 (m)	1.26–1.74 (m)	1.26–1.74 (m)
9	1.59–1.70 (m)	3.83–3.98 (m)	3.83–3.95 (m)	1.26–1.57 (m)	1.28–1.75 (m)	3.80–3.92 (m)	1.26–1.74 (m)	1.46–1.74 (m)
10	3.58–3.61 (m)	1.79–2.04 (m)	1.62–1.72 (m)	1.26–1.57 (m)	3.80–3.92 (m)	1.96–2.04 (m), 1.63–1.75 (m)	3.80–3.89 (m)	3.58–3.64 (m)
11	1.59–1.70 (m)	1.79–2.04 (m)	1.96–2.02 (m)	1.44–1.57 (m)	1.96–2.07 (m), 1.82–1.94 (m)	1.96–2.04 (m), 1.63–1.75 (m)	1.98–2.05 (m), 1.48–1.74 (m)	1.46–1.74 (m)
12	1.27–1.56 (m)	3.83–3.98 (m)	3.83–3.95 (m)	3.39–3.41 (m)	1.96–2.07 (m), 1.82–1.94 (m)	3.80–3.92 (m)	1.98–2.05 (m), 1.48–1.74 (m)	1.26–1.74 (m)
13	1.27–1.56 (m)	3.83–3.98 (m)	3.83–3.95 (m)	3.39–3.41 (m)	3.80–3.92 (m)	3.40–3.47 (m)	3.80–3.89 (m)	1.26–1.74 (m)
14	1.27–1.56 (m)	1.79–2.04 (m)	1.96–2.02 (m)	1.44–1.57 (m)	3.40–3.47 (m)	1.28–1.75 (m)	3.41–3.44 (m)	1.26–1.74 (m)
15	1.27–1.56 (m)	1.79–2.04 (m), 1.45–1.68 (m)	1.62–1.72 (m)	1.62–1.72 (m)	1.96–2.07 (m), 1.82–1.94 (m)	1.28–1.75 (m)	1.48–1.74 (m)	1.26–1.74 (m)
16	1.44–1.58 (m)	3.83–3.98 (m)	3.83–3.95 (m)	3.39–3.41 (m)	1.96–2.07 (m), 1.82–1.94 (m)	3.40–3.47 (m)	1.26–1.74 (m)	1.46–1.74 (m)
17	3.39–3.44 (m)	3.83–3.98 (m)	3.39–3.44 (m)	3.78–3.96 (m)	3.40–3.47 (m)	3.80–3.92 (m)	1.26–1.74 (m)	3.40–3.47 (m)
18	3.83–3.97 (m)	1.45–1.68 (m)	1.45–1.60 (m)	1.79–2.01 (m)	3.80–3.92 (m)	1.96–2.04 (m), 1.63–1.75 (m)	3.41–3.44 (m)	3.77–3.85 (m)
19	1.79–2.03 (m)	1.28–1.58 (m)	1.28–1.60 (m)	1.79–2.01 (m)	1.84–2.06 (m)	1.96–2.04 (m), 1.63–1.75 (m)	3.41–3.44 (m)	1.95–2.03 (m), 1.46–1.74 (m)
20	1.79–2.03 (m)	1.28–1.58 (m)	1.28–1.60 (m)	3.78–3.96 (m)	1.84–2.06 (m)	3.80–3.92 (m)	1.26–1.74 (m)	1.95–2.03 (m), 1.46–1.74 (m)
21	3.83–3.97 (m)	1.28–1.58 (m)	1.28–1.60 (m)	3.78–3.96 (m)	3.80–3.92 (m)	3.40–3.47 (m)	1.26–1.74 (m)	3.77–3.85 (m)
22	3.83–3.97 (m)	1.28–1.58 (m)	1.28–1.60 (m)	1.79–2.01 (m)	3.80–3.92 (m)	1.49–1.75 (m)	1.26–1.74 (m)	3.40–3.47 (m)
23	1.79–2.03 (m)	1.28–1.58 (m)	1.28–1.60 (m)	1.79–2.01 (m), 1.49–1.67 (m)	1.28–1.75 (m)	1.28–1.75 (m)	1.26–1.74 (m)	1.46–1.74 (m)
24	1.79–2.03 (m), 1.59–1.70 (m)	1.28–1.58 (m)	1.28–1.60 (m)	3.78–3.96 (m)	1.28–1.75 (m)	1.28–1.75 (m)	1.26–1.74 (m)	1.26–1.74 (m)
25	3.83–3.97 (m)	1.28–1.58 (m)	1.28–1.60 (m)	3.78–3.96 (m)	1.28–1.75 (m)	1.28–1.75 (m)	1.26–1.74 (m)	1.26–1.74 (m)
26	3.83–3.97 (m)	1.28–1.58 (m)	1.28–1.60 (m)	1.44–1.57 (m)	1.28–1.75 (m)	1.28–1.75 (m)	1.26–1.74 (m)	1.26–1.74 (m)
27	1.59–1.70 (m)	1.28–1.58 (m)	1.28–1.60 (m)	1.26–1.57 (m)	1.28–1.75 (m)	1.28–1.75 (m)	1.26–1.74 (m)	1.26–1.74 (m)
28–31	1.27–1.56 (m)	1.28–1.58 (m)	1.28–1.60 (m)	1.26–1.57 (m)	1.28–1.75 (m)	1.28–1.75 (m)	1.26–1.74 (m)	1.26–1.74 (m)
32	1.27–1.56 (m)	1.28–1.58 (m)	1.28–1.60 (m)	1.26–1.57 (m)	1.28–1.75 (m)	1.28–1.75 (m)	0.88 (t, 6.8)	0.88 (t, 6.8)
33	1.44–1.56 (m)	1.45–1.68 (m)	1.45–1.60 (m)	1.44–1.57 (m)	1.28–1.75 (m)	1.28–1.75 (m)	7.21 (d, 1.1)	7.21 (d, 1.2)
34	0.91 (t, 6.8)	0.90 (t, 6.7)	0.90 (t, 6.7)	0.90 (t, 6.7)	0.90 (t, 6.8)	0.90 (t, 6.7)	5.07 (dq, 6.8, 1.2)	5.06 (dq, 6.8, 1.2)
35	7.00 (d, 1.7)	7.00 (d, 1.0)	7.00 (d, 1.5)	7.00 (d, 1.5)	7.20 (d, 1.5)	7.01 (d, 1.7)	1.44 (d, 6.8)	1.43 (d, 6.8)
36	5.01 (qd, 6.8, 1.8)	5.01 (qd, 6.8, 1.3)	5.01 (qd, 6.8, 1.8)	5.01 (qd, 6.8, 1.8)	5.08 (dq, 6.8, 1.6)	5.02 (dq, 6.8, 1.9)	–	–
37	1.42 (d, 6.8)	1.42 (d, 6.8)	1.43 (d, 6.8)	1.41 (d, 6.8)	1.45 (d, 6.8)	1.43 (d, 6.8)	–	–

Compound **3**, a colorless oil, shared a molecular formula of $C_{37}H_{66}O_6$ with **2** (m/z 607.4879 $[M + H]^+$, calcd. 607.4932). A positive reaction to Raymond's reagent suggested the existence of a γ -lactone. The signals at δ_H 7.00 (1H, d, $J = 1.5$ Hz, H-35), 5.01 (1H, dq, $J = 6.8, 1.8$ Hz, H-36), 1.43 (3H, d, $J = 6.8$ Hz, H-37) and δ_C 173.9 (C-1), 134.4 (C-2), 148.8 (C-35), 77.4 (C-36) and 19.2 (C-37) confirmed the presence of lactone. Signal at 2.28 (2H, t, $J = 7.7$ Hz, H-3) indicated there is no hydroxyl group at C-4^[3]. The signals at δ_H 3.83–3.95 (4H, m, H-9, 12, 13, 16), 3.38–3.43 (2H, m, H-8, 17) and those at δ_C 83.2 (C-9, 16), 81.8 (C-12, 13), 74.1 (C-8, 17) in the 1H and ^{13}C NMR spectra are the characteristic of the presence of symmetrical two adjacent bis-THF unit with two flanking OH groups, and the relative stereochemistry was established as *th/t/th/t/th* (*threo/trans/threo/trans/threo*) by carefully comparison of NMR data with a series of Asimicin-type ACGs^[14–15]. The position of bis-THF was determined on the basis of the ESIMSMS fragments (387, 249 and 167) (Fig. 2).

Compound **4** was obtained as colorless oil. The molecular formula was determined as $C_{37}H_{66}O_8$ by HR-ESIMS data (m/z 639.4963 $[M + H]^+$, calcd. for 639.4831). The NMR data (Tables 1 and 2) analysis showed its structure was closely related to that of **1**, with the only difference being at δ_C 74.2, 74.6 and δ_H 3.39–3.41 (2H, m) for **4**, indicating a fourth hydroxy in **4**, and a existence of a vicinal diol group by comparison with that of glabranin^[16] and 4-acetyl gigantetrocin A^[17]. The location of vicinal diol group was determined by carefully analysis of ESIMSMS data (m/z 415, 335, 265, 245) (Fig. 2). The THF rings were located at C-16 to C-25, on basis of the fragment ions at m/z 373, 307, 293, 209 (Fig. 2).

Compound **5** displayed a molecular formula of $C_{37}H_{66}O_8$ by HR-ESIMS (m/z 639.4980 $[M + H]^+$, calcd. 639.4831). The presence of two nonadjacent bis-THF rings with three flanking OH groups was determined by 1H NMR signals at δ_H 3.80–3.92 (6H, m, H-4, 10, 13, 18, 21, 22), 3.40–3.47 (2H, m, H-14, 17) and ^{13}C NMR signals at δ_C 83.3 (C-18), 82.2 (C-21), 82.0 (C-13), 79.3 (C-10), 74.6 (C-14), 74.5 (C-17), 71.6 (C-22). The signals at δ_H 7.20 (1H, d, $J = 1.5$ Hz, H-35), 5.08 (1H, dq, $J = 6.8, 1.6z$ Hz, H-36), 1.45 (3H, d, $J = 6.8$ Hz, H-37) and those at δ_C 174.6 (C-1), 131.2 (C-2), 151.8 (C-35), 78.0 (C-36), 19.1 (C-37) were characteristic of a terminal α, β -unsaturated γ -lactone. 1H NMR signals at 2.41 (1H, dd, $J = 15.2, 8.3$ Hz, H-3) and 2.54 (1H, d, $J = 15.1, 3.4$ Hz, H-3) indicated the presence of a hydroxyl at C-4^[18]. The THF rings with flanking hydroxyls were located at C-10 to C-22 (Fig. 2), on the basis of ESIMSMS fragments at 369, 289, 249 and 211. The relative stereochemistry across the THF rings and flanking hydroxyls of **5** was assigned as *t/th-th/t/er* (*trans/threo-threo/trans/erythro*) by comparison of NMR data with a series of bullatalicin-type compounds^[3, 19].

Compound **6** was isolated as a white waxy with molecular formula of $C_{37}H_{66}O_7$, on basis of its HR-ESIMS fragment

(m/z 623.4789 $[M + H]^+$, calcd for 623.4881). The NMR data (Tables 1 and 2) displayed characteristic signals for a terminal unsaturated lactone. The signal at 2.28 (2H, t, $J = 7.8$ Hz, H-3) indicated an absence of hydroxyl at C-4^[3]. NMR data at δ_H 3.80–3.92 (4H, m, H-9, 12, 17, 20), 3.40–3.47 (3H, m, H-13, 16, 21) and those at δ_C 82.7 (C-17, 20), 82.0 (C-12), 79.4 (C-9), 74.5 (C-21), 74.3 (C-16) 74.1 (C-13) indicated the presence of two nonadjacent bis-THF rings with three flanking hydroxyl groups, and the relative stereochemistry of those was *t/th-th/t/th* (*trans/threo-threo/trans/threo*) by comparison of NMR data with a series of bullatanocin-type compounds^[20–21]. The bis-THF rings and the flanking OH groups were located at C-9 to C-21 on the basis of MS² fragments at m/z 383, 371, 319, 291, 263 and 193 (Fig. 2).

Compound **7**, a white waxy, gave a molecular formula of $C_{35}H_{64}O_7$, deduced from HR-ESIMS fragment at m/z 597.4621 $[M + H]^+$ (calcd. 597.4725). The NMR data at δ_H 7.21 (1H, d, $J = 1.1$ Hz, H-33), 5.07 (1H, dq, $J = 6.8, 1.2$ Hz, H-34), 1.44 (3H, d, $J = 6.8$ Hz, H-35) and those at δ_C 174.7 (C-1), 131.1 (C-2), 151.9 (C-33), 78.0 (C-34), 19.1 (C-35) were characteristic of a terminal α, β -unsaturated γ -lactone. 1H NMR signals at 2.40 (1H, dd, $J = 15.1, 8.2$ Hz, H-3) and 2.52 (1H, d, $J = 15.1, 3.3$ Hz, H-3) indicated the presence of hydroxyl at C-4^[18]. NMR data (Tabs 1 and 2) indicated the presence of a THF ring with one flanking hydroxyl and two other OH groups. The relative configuration of THF ring and flanking hydroxyl was assigned as *th/t* (*threo/trans*)^[16, 22–23]. The position of them was located at C-10 to C-14 by analysis of the fragment ions at m/z 289 and 191 (Fig. 2). The proton signal at δ_H 3.41–3.44 (3H, m) and the carbon signals at δ_C 74.3 and 74.5 were suspected to represent a 1,2-diol group^[16–17]. The position of two adjacent hydroxyls was assigned by carefully analysis on MSMS data (m/z 335, 329, 205) (Fig. 2).

Compound **8** had a molecular formula of $C_{35}H_{64}O_7$ based on the HR-ESIMS ($[M + H]^+$ m/z 597.4636, calcd. 597.4725). The NMR data (Tables 1 and 2) of **8** suggested the presence of a terminal α, β -unsaturated γ -lactone and a presence of a hydroxyl at C-4^[18]. NMR signals at δ_H 3.77–3.85 (3H, m, H-4, 18, 21), 3.58–3.64 (1H, m, H-10), 3.40–3.47 (2H, m, H-17, 22) and those at δ_C 82.8 (C-21), 82.5 (C-18), 74.3 (C-22), 74.1 (C-17), 71.5 (C-10) indicated the existence of a THF ring with two flanking OH groups in a *th/t/th* (*threo/trans/threo*) configuration^[23–24] and a fourth hydroxyl. The location was at C-17 to C-22, on the basis of ESIMS² data m/z 335, 289, 253. The position of fourth OH group was determined by m/z 205 and 191 (Fig. 2).

Compounds **1–9** were evaluated for their anticancer activities against three MDR cancer cell lines including liver cancer SMMC 7721/Adr, breast cancer MCF-7/Adr and lung cancer A549/T (Table 3). All tested compounds showed promising cytotoxicity against these MDR cancer cell lines, and cytotoxicity of them is much stronger than Adriamycin against SMMC 7721/Adr.

Table 3 The cytotoxicity of compound 1–9 from *A. squamosa*

Sample	IC ₅₀ (μmol·L ⁻¹)		
	SMMC 7721/Adr	MCF-7/Adr	A549/T
squamotin A (1)	2.56	12.42	7.44
squamotin B (2)	8.54	22.55	5.23
squamotin C (3)	14.10	54.97	11.04
squamotin D (4)	1.43	2.88	7.27
annosquatin IV (5)	5.68	4.71	6.13
annosquatin V (6)	7.88	2.07	3.21
muricin O (7)	5.43	5.78	8.37
squamosten B (8)	5.40	4.03	10.06
gigantecin (9)	15.45	20.58	36.33
Adr	1815	9.99	7.96

Materials and Methods

General experimental procedures

NMR spectroscopic data were collected on a Bruker AV-400 spectrometer with deuterated chloroform (CDCl₃) as solvents. HR-ESIMS were measured on an ESI-Q-TOF-MS (Triple TOF 5600, AB Sciex). Optical rotations were recorded in EtOH on a Rudolph AUTOPOL III high sensitive polarimeter (America). The Ultraviolet spectra were measured on a HP 8451A diode array spectrophotometer. Silica gel (100–200 mesh, 200–300 mesh) (Qingdao marine Chemical Ltd., Qingdao, China), ODS-A (YMC Co., Japan) was used for column chromatography. Preparative HPLC were performed on Shimadzu LC-20A (Shimadzu, Japan) with a Waters ODS column (250 mm × 19 mm i.d., 5 μm, Part No. 186004021, Waters, America). Unless otherwise specified, all chemicals and solvents were purchased from Nanjing Chemical Reagent Co., Ltd. (Nanjing, China)

Plant material

A. squamosa seeds were collected in Lincang City of Yunnan province in China, and identified by Prof. CHEN Jian-Wei (Nanjing University of Chinese Medicine). Sample was authenticated and deposited in Pharmaceutical Institute of Nanjing University of Chinese Medicine (No. 20150124).

Extraction and isolation

The air-dried seeds (22.5 kg) were powdered and extracted as previously described^[25]. As a result, 3.3 kg of supercritical fluid CO₂ extraction (SFE) was obtained. This extraction was passed through silica gel (200–300 mesh) with a gradient of increasing polarity with Pet-ether/EtOAc/MeOH, and the resulting fractions were analyzed by TLC on silica gel. As a result, twelve fractions (Fr 1–Fr 12) were obtained. Fr 7 (171.1 g) was loaded on silica gel column and eluted by Pet-ether/EtOAc/MeOH (100 : 1 : 0–0 : 10 : 1, and further purified on an ODS column (MeOH–H₂O, 95 : 5; 8 mL·min⁻¹ and 220 nm detection) to yield **2** (209 mg), **3** (53 mg), **10** (37 mg). Fr 8 (60.0 g) was loaded on a silica gel column and eluted with Pet-ether/EtOAc/MeOH (2 : 1 : 0–0 : 25 : 1), and further

purified on an ODS column (MeOH–H₂O, 9:1; 10 mL·min⁻¹ and 220 nm detection) to yield **1** (18 mg), **6** (21 mg), **11** (537 mg) and **12** (164 mg). Fr 10 (23.7 g) was separated by octadecyl-silylated silica at a MPLC (medium-pressure liquid chromatography) and further purified on an ODS column; (MeOH–H₂O, 75 : 25; 8 mL·min⁻¹ and 220 nm detection) to yield **4** (12 mg), **5** (21 mg), **7** (17 mg), **8** (31 mg) and **9** (22 mg).

Squamotin A (**1**): a white waxy, mp 60–62 °C; $[\alpha]_D^{29} + 16.3^\circ$ (*c* 0.10, EtOH); IR (KBr) ν_{\max} 3379, 2917, 2851 and 1743; ¹H and ¹³C-NMR: showed in Tab 1 and Tab 2; HR-ESIMS *m/z* 623.4921 [M + H]⁺ (C₃₇H₆₇O₇, calcd. 623.4881).

Squamotin B (**2**): a white waxy, mp 62–64 °C; $[\alpha]_D^{29} + 10.2^\circ$ (*c* 0.13, EtOH); IR (KBr) ν_{\max} 3421, 2917, 2850 and 1744; ¹H and ¹³C-NMR: showed in Tables 1 and 2; HR-ESIMS *m/z* 607.5068 [M + H]⁺ (C₃₇H₆₇O₆, calcd. 607.4932).

Squamotin C (**3**): colorless oil, $[\alpha]_D^{29} + 0.3^\circ$ (*c* 0.31, EtOH); IR (KBr) ν_{\max} 3421, 2927, 2855 and 1757; ¹H and ¹³C-NMR: showed in Tables 1 and 2; HR-ESIMS *m/z* 607.4879 [M + H]⁺ (C₃₇H₆₇O₆, calcd. 607.4932).

Squamotin D (**4**): colorless oil; $[\alpha]_D^{29} + 1.4^\circ$ (*c* 0.21, EtOH); IR (KBr) ν_{\max} 3425, 2927, 2855 and 1757; ¹H and ¹³C-NMR: showed in Tables 1 and 2; HR-ESIMS *m/z* 639.4963 [M + H]⁺ (C₃₇H₆₇O₈, calcd. 639.4831).

Annosquatin IV (**5**): white waxy, mp 109–111 °C; $[\alpha]_D^{29} + 4.0^\circ$ (*c* 0.12, EtOH); IR (KBr) ν_{\max} 3431, 2922, 2851 and 1751; ¹H and ¹³C-NMR: showed in Tables 1 and 2; HR-ESIMS *m/z* 639.4980 [M + H]⁺ (C₃₇H₆₇O₈, calcd. 639.4831).

Annosquatin V (**6**): white waxy, mp 66–68 °C; $[\alpha]_D^{29} + 8.0^\circ$ (*c* 0.10, EtOH); IR (KBr) ν_{\max} 3431, 2920, 2851 and 1740; ¹H and ¹³C-NMR: showed in Tab 1 and Table 2; HR-ESIMS *m/z* 623.4789 [M + H]⁺ (C₃₇H₆₇O₇, calcd. 623.4881)

Muricin O (**7**): white waxy, mp 82–84 °C; $[\alpha]_D^{29} + 6.7^\circ$ (*c* = 0.10, EtOH); IR (KBr) ν_{\max} 3422, 2921, 2850 and 1752; ¹H and ¹³C-NMR: showed in Tables 1 and 2; HR-ESIMS *m/z* 597.4621 [M + H]⁺ (C₃₅H₆₅O₇, calcd. 597.4725).

Squamosten B (**8**): white waxy, mp 62–64 °C; $[\alpha]_D^{29} + 10.7^\circ$ (*c* 0.08, EtOH); IR (KBr) ν_{\max} 3431, 2921, 2851 and 1736; ¹H and ¹³C-NMR: showed in Tables 1 and 2; HR-ESIMS *m/z* 597.4636 [M + H]⁺ (C₃₅H₆₅O₇, calcd. 597.4725).

Anticancer activity assay

Compounds **1–9** were evaluated for their cytotoxicity against three MDR cancer cell lines (liver cancer SMMC 7721/Adr, breast cancer MCF-7/Adr and lung cancer A549/T), using the MTT method in 96-well plates. Adriamycin was used as a positive control.

References

- [1] Ma CY, Chen YY, Chen JW, et al. A review on *Annona squamosa* L.: phytochemicals and biological activities [J]. *Am J Chin Med*, 2017, 45(5): 933-964.

- [2] Senica M, Stampar F, Veberic R, et al. Fruit seeds of the Rosaceae family: a waste, new life, or a danger to human health? [J]. *J Agric Food Chem*, 2017, **65**(48): 10621-10629.
- [3] Chen Y, Chen JW, Wang Y, et al. Six cytotoxic annonaceous acetogenins from *Annona squamosa* seeds [J]. *Food Chem*, 2012, **135**(3): 960-966.
- [4] Vila-Nova NS, de Morais SM, Falcao MJC, et al. Leishmanicidal activity and cytotoxicity of compounds from two *Annonacea* species cultivated in northeastern Brazil [J]. *Rev Soc Bras Med Trop*, 2011, **44**(5): 567-571.
- [5] Dang QL, Kim WK, Nguyen CM, et al. Nematicidal and anti-fungal activities of annonaceous acetogenins from *Annona squamosa* against various plant pathogens [J]. *J Agric Food Chem*, 2011, **59**(20): 11160-11167.
- [6] Victor RP, Ronald RW, Vinood BP. *Nuts and Seeds in Health and Disease Prevention* [M]. London: Elsevier Academic Press, 2011: 439-445.
- [7] Ma CY, Wang QW, Shi YY, et al. Three new antitumor annonaceous acetogenins from the seeds of *Annona squamosa* [J]. *Nat Prod Res*, 2017, **31**(18): 2085-2090.
- [8] Hoye TR, Eklov BM, Jeon J, et al. Sequencing of three-component olefin metatheses: total synthesis of either (+)-gigantecin or (+)-14-deoxy-9-oxygigantecin [J]. *Organic Letters*, 2006, **8**(15): 3383-3386.
- [9] Kawazu K, Alcantara JP, Kobayashi A. Isolation and structure of neoannonin, a novel insecticidal compound from the seeds of *Annona squamosa* [J]. *Agric Biol Chem*, 1989, **53**(10): 2719-2722.
- [10] Miao YJ, Xu XF, Yuan F, et al. Four cytotoxic annonaceous acetogenins from the seeds of *Annona squamosa* [J]. *Nat Prod Res*, 2016, **30**(11): 1273-1279.
- [11] Yu JG, Luo XZ, Sun L, et al. Chemical constituents from the seeds of *Annona squamosa* [J]. *Acta Pharm Sin*, 2005, **40**(2): 153-158.
- [12] Chen Y, Yu DQ. Chemical classification and NMR identification of the terminal lactone ring and tetrahydrofuran ring of the anti-cancer active ingredient [J]. *Acta Pharm Sin*, 1998, **33**(7): 553-560.
- [13] Lima LARD, Pimenta LPS, Boaventura MAD. Two new adjacent bis-tetrahydrofuran annonaceous acetogenins from seeds of *Annona cornifolia* [J]. *Planta Med*, 2009, **75**(1): 80-83.
- [14] Zhao GX, Miesbauer LR, Smith DL, et al. Asimin, asimiacin, and asiminecin-novel highly cytotoxic asimicin isomers from *Asimina-Triloba* [J]. *J Med Chem*, 1994, **37**(13): 1971-1976.
- [15] Duret P, Gromek D, Hocquemiller R, et al. Isolation and structure of three new bis-tetrahydrofuran acetogenins from the roots of *Annona cherimolia* [J]. *J Nat Prod*, 1994, **57**(7): 911-916.
- [16] Gallardo T, Aragon R, Tormo JR, et al. Acetogenins from *Annona glabra* seeds [J]. *Phytochemistry*, 1998, **47**(5): 811-816.
- [17] Zeng L, Zhang Y, Ye Q, et al. Cis-gigantrionenin and 4-acetyl gigantetrocin A, two new bioactive annonaceous acetogenins from *Goniothalamus giganteus*, and the stereochemistries of acetogenin 1, 2, 5-triols [J]. *Bioorg Med Chem*, 1996, **4**(8): 1271-1279.
- [18] Chen Y, Chen JW, Li X. Cytotoxic bistetrahydrofuran annonaceous acetogenins from the seeds of *Annona squamosa* [J]. *J Nat Prod*, 2011, **74**(11): 2477-2481.
- [19] Cortes D, Myint SH, Dupont B, et al. Bioactive acetogenins from seeds of *Annona Cherimolia* [J]. *Phytochemistry*, 1993, **32**(6): 1475-1482.
- [20] Ratnayake S, Gu ZM, Miesbauer LR, et al. Parvifloracin and Parviflorin-cytotoxic bistetrahydrofuran acetogenins with 35 carbons from *Asimina parviflora* (Annonaceae) [J]. *Can J Chem*, 1994, **72**(2): 287-293.
- [21] Fujimoto Y, Murasaki C, Shimada H, et al. Annonaceous acetogenins from the seeds of *Annona squamosa*. Non-adjacent bis-tetrahydrofuran acetogenins [J]. *Chem Pharm Bull (Tokyo)*, 1994, **42**(6): 1175-1184.
- [22] Sun S, Liu JC, Kadouh H, et al. Three new anti-proliferative annonaceous acetogenins with mono-tetrahydrofuran ring from graviola fruit (*Annona muricata*) [J]. *Bioorg Med Chem Lett*, 2014, **24**(12): 2773-2776.
- [23] Liaw CC, Chang FR, Chen SL, et al. Novel cytotoxic monotetrahydrofuranic annonaceous acetogenins from *Annona montana* [J]. *Bioorg Med Chem*, 2005, **13**(15): 4767-4776.
- [24] Ye Q, Zeng L, Zhang Y, et al. Longicin and Goniothalamicinone-novel bioactive monotetrahydrofuran acetogenins from *Asimina longifolia* [J]. *J Nat Prod*, 1995, **58**(9): 1398-1406.
- [25] Yang H, Li X. Study the optimum extraction of annonaceous acetogenins from seeds of *Annona Glabra* L. by supercritical fluid CO₂ extraction (SFE) [J]. *J US-China Med Sci*, 2008, **5**(1): 56-59.

Cite this article as: MA Cheng-Yao, LU Jia-Hui, LI Xiang, LIU Xiao, CHEN Jian-Wei. Eight New Cytotoxic Annonaceous Acetogenins from the Seeds of *Annona squamosa* [J]. *Chin J Nat Med*, 2019, **17**(4): 291-297.